Skip to main content
رجوع
RMD logo

ResMed Inc.

جودة البيانات: 100%
RMD
NYSE Healthcare Medical - Instruments & Supplies
KWD 228.19
▲ KWD 0.22 (0.10%)
القيمة السوقية: 33.31B
نطاق اليوم
KWD 224.92 KWD 231.45
نطاق 52 أسبوعًا
KWD 199.92 KWD 293.81
حجم التداول
1,000,692
متوسط 50 يوم / 200 يوم
KWD 252.88 / KWD 260.16
الإغلاق السابق
KWD 227.97

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 23.8 0.3
P/B 5.6 2.9
ROE % 25.9 3.7
Net Margin % 27.2 3.8
Rev Growth 5Y % 12.6 10.0
D/E 0.1 0.2

السعر المستهدف للمحللين

Hold
KWD 295.880 +29.7%
Low: KWD 265.000 High: KWD 345.000
مكرر الربحية المستقبلي
20.6
ربحية السهم المستقبلية
KWD 11.054
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
5.6 B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 16.200
KWD 15.910 – KWD 16.437
 7.8 B 4
FY2029 KWD 14.383
KWD 14.125 – KWD 14.594
 7 B 3
FY2028 KWD 13.431
KWD 12.124 – KWD 14.291
 6.5 B 9

النقاط الرئيسية

Revenue grew 12.64% annually over 5 years — strong growth
Earnings grew 37.20% over the past year
ROE of 25.86% indicates high profitability
Net margin of 27.22% shows strong profitability
Debt/Equity of 0.14 — conservative balance sheet
Generating 1.66B in free cash flow

النمو

Revenue Growth (5Y)
12.64%
Revenue (1Y)9.84%
Earnings (1Y)37.20%
FCF Growth (3Y)72.37%

الجودة

Return on Equity
25.86%
ROIC18.53%
Net Margin27.22%
Op. Margin32.75%

الأمان

Debt / Equity
0.14
Current Ratio3.44
Interest Coverage133.66

التقييم

P/E Ratio
23.78
P/B Ratio5.58
EV/EBITDA19.55
Dividend Yield0.01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 9.84% Revenue Growth (3Y) 10.39%
Earnings Growth (1Y) 37.20% Earnings Growth (3Y) 24.92%
Revenue Growth (5Y) 12.64% Earnings Growth (5Y) 31.08%
Profitability
Revenue (TTM) 5.15B Net Income (TTM) 1.40B
ROE 25.86% ROA 17.14%
Gross Margin 59.36% Operating Margin 32.75%
Net Margin 27.22% Free Cash Flow (TTM) 1.66B
ROIC 18.53% FCF Growth (3Y) 72.37%
Safety
Debt / Equity 0.14 Current Ratio 3.44
Interest Coverage 133.66 Dividend Yield 0.01%
Valuation
P/E Ratio 23.78 P/B Ratio 5.58
P/S Ratio 6.47 PEG Ratio 0.72
EV/EBITDA 19.55 Dividend Yield 0.01%
Market Cap 33.31B Enterprise Value 32.95B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 5.15B 4.69B 4.22B 3.58B 3.20B
Net Income 1.40B 1.02B 897.56M 779.44M 474.51M
EPS (Diluted) 9.51 6.92 6.09 5.30 3.24
Gross Profit 3.05B 2.66B 2.36B 2.02B 1.84B
Operating Income 1.69B 1.32B 1.13B 1.00B 903.68M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 8.17B 6.87B 6.75B 5.10B 4.73B
Total Liabilities 2.21B 2.01B 2.62B 1.74B 1.84B
Shareholders' Equity 5.97B 4.86B 4.13B 3.36B 2.89B
Total Debt 851.81M 873.94M 1.58B 917.55M 793.72M
Cash & Equivalents 1.21B 238.36M 227.89M 273.71M 295.28M
Current Assets 3.51B 2.36B 2.37B 1.93B 1.57B
Current Liabilities 1.02B 910.66M 758.53M 689.30M 911.77M

درجات الاستراتيجيات

This stock passed the criteria for 5 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#932 of 1052
24
Custom Capital Light Compounder
#187 of 218
25
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#203 of 332
46
Custom Balanced Risk
#94 of 151
43
Custom Lower Risk
#120 of 140
34

النشاط الأخير

دخل Cash Flow Compounder
Mar 25, 2026
دخل Capital Light Compounder
Mar 25, 2026
دخل Balanced Risk
Mar 25, 2026
دخل Lower Risk
Mar 25, 2026
دخل Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026